BASEL, Switzerland,
Nov. 21, 2017 /PRNewswire/ -- Myovant
Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative
therapies for women's health and endocrine diseases, today
announced that Lynn Seely, M.D.,
President and Chief Executive Officer of Myovant Sciences and
Frank Karbe, Chief Financial Officer
of Myovant Sciences, will participate in a fireside chat at the
Evercore ISI BioPharma Catalyst / Deep Dive Conference in
Boston, Massachusetts on
November 29, 2017 at 2:00 p.m. ET.
The event will be webcast live and may be accessed via the
Events page under the Investors and Media section of Myovant's
website at www.myovant.com. Please connect to the company's website
at least 15 minutes prior to the presentation to ensure adequate
time for any software download that may be required to listen to
the webcast. A replay will also be available at the same location
for 30 days following the conference.
About Myovant Sciences
Myovant Sciences is a clinical-stage biopharmaceutical company
focused on developing and commercializing innovative therapies for
women's health and endocrine diseases. Myovant's lead product
candidate is relugolix, an oral, once-daily, small molecule that
acts as a gonadotropin-releasing hormone receptor antagonist.
Myovant has initiated three clinical programs for relugolix
consisting of five international Phase 3 clinical trials, two in
women with heavy menstrual bleeding associated with uterine
fibroids (LIBERTY 1 & 2), two in women with
endometriosis-associated pain (SPIRIT 1 & 2), and one in men
with advanced prostate cancer (HERO). Myovant is simultaneously
developing MVT-602, a kisspeptin agonist, for the treatment of
female infertility as part of assisted reproduction. Takeda
Pharmaceuticals International AG has granted Myovant an exclusive,
worldwide license to develop and commercialize relugolix (excluding
Japan and certain other Asian
countries where Takeda retains exclusive rights) and an exclusive
license to develop and commercialize MVT-602 in all countries
worldwide. Over time, the company intends to expand its development
pipeline to include other potential treatments for women's health
and endocrine diseases. For more information, please visit the
company's website at www.myovant.com.
Investor Contact:
DeDe
Sheel
Investor Relations
Myovant Sciences, Inc.
investors@myovant.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myovant-sciences-to-participate-in-the-evercore-isi-biopharma-catalyst--deep-dive-conference-300559971.html
SOURCE Myovant Sciences